The High Frequency of the C282Y-Mutant HFE Gene in Northeast Iran; New Finding or Genotyping Error?


Heidar Sharafi 1 , 2 , Seyed Moayed Alavian 1 , 2 , *

1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran

2 Middle East Liver Diseases (MELD) Center, Tehran, IR Iran

How to Cite: Sharafi H, Alavian S M. The High Frequency of the C282Y-Mutant HFE Gene in Northeast Iran; New Finding or Genotyping Error?, Iran Red Crescent Med J. 2016 ; 18(12):e42335. doi: 10.5812/ircmj.42335.


Iranian Red Crescent Medical Journal: 18 (12); e42335
Published Online: December 4, 2016
Article Type: Letter
Received: September 16, 2016
Accepted: November 26, 2016





Hereditary Hemochromatosis C282Y

Copyright © 2016, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Dear Editor,

We read with great interest the article by Gerayli et al. (1) in your esteemed journal recently. The authors assessed the H63D and C282Y polymorphisms of the HFE gene in Iranian patients from north east Iran with hepatitis C as well as healthy individuals. They found the distribution of C282Y CC, CY and YY genotypes in hepatitis C patients as follow: 84.61%, 10.76% and 4.61%, respectively. Moreover, the frequency of C282Y CC, CY and YY genotypes in healthy individuals was found to be 64.61%, 0% and 35.38%, respectively.

The C282Y polymorphism of the HFE gene is the main genetic factor in hereditary hemochromatosis (HH), which is used as the routine marker for molecular diagnosis of HH (2). In a study, 91% of the population in United Kingdom with HH was found to be homozygous for C282Y while only 1% of the control group were homozygous for C282Y (3). We are writing this letter to express our concern regarding the results of the study done by Gerayli et al. (1). They found a high prevalence (> 15%) of C282Y-mutant genotypes (CY and YY) in both groups of Iranian patients with hepatitis C as well as healthy individuals. In previous studies from Iran, the mutant genotypes of this polymorphism was rarely observed in healthy Iranian individuals (4, 5) and even in Iranian patients with liver diseases and HH (5-7). While the data presented by Gerayli et al. (1) regarding the high prevalence of C282Y-mutant genotypes in northeast Iran can be of great interest it should however be noted that this high prevalence of mutant-C282Y genotypes can be a result of genotyping error. It is important to note that distribution of the C282Y genotypes in the study done by Gerayli et al. (1), on healthy individuals was deviated (P < 0.05) from Hardy-Weinberg Equilibrium, which is in favor of genotyping error.

In conclusion, the frequency of the C282Y genotypes in individuals from northeast Iran should be investigated by another study using a valid method for confirmation of the results given by Gerayli et al. (1). Moreover, it is very important to validate the results of the methods in molecular studies with another gold-standard method even if it was developed, used and described by others (8).



  • 1.

    Gerayli S, Pasdar A, Shakeri MT, Sepahi S, Hoseini SM, Ahadi M. Haplotype Analysis of Hemochromatosis Gene Polymorphisms in Chronic Hepatitis C Virus Infection: A Case Control Study. Iran Red Crescent Med J. 2016; 18(6) : 24675 [DOI]

  • 2.

    European Association For The Study Of The L. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010; 53(1) : 3 -22 [DOI][PubMed]

  • 3.

    A simple genetic test identifies 90% of UK patients with haemochromatosis. The UK Haemochromatosis Consortium. Gut. 1997; 41(6) : 841 -4 [DOI][PubMed]

  • 4.

    Bakayev V, Ignatiev I, Jazayeri M, Mohaghegh H, Zborovsky S, Zali MR. Duplex polymerase chain reaction-restriction fragment length polymorphism assay for rapid detection of HFE mutations-C282Y occurs with a low frequency in Tehran's population. J Hepatol. 2004; 40(3) : 559 -60 [DOI][PubMed]

  • 5.

    Ghaziani T, Alavian SM, Zali MR, Shahraz S, Agah M, Jensen KP, et al. Serum measures of iron status and HFE gene mutations in patients with hepatitis B virus infection. Hepatol Res. 2007; 37(3) : 172 -8 [DOI][PubMed]

  • 6.

    Jowkar Z, Geramizadeh B, Shariat M. Frequency of Two Common HFE Gene Mutations (C282Y and H63D) in a Group of Iranian Patients With Cryptogenic Cirrhosis. Hepat Mon. 2011; 11(11) : 887 -9 [DOI][PubMed]

  • 7.

    Zamani F, Bagheri Z, Bayat M, Fereshtehnejad SM, Basi A, Najmabadi H, et al. Iranian hereditary hemochromatosis patients: baseline characteristics, laboratory data and gene mutations. Med Sci Monit. 2012; 18(10) : 622 -9 [PubMed]

  • 8.

    Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Mehrnoush L, et al. Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response. Hepat Mon. 2012; 12(3) : 190 -5 [DOI][PubMed]